Total Reports
17
FDA CVM filings
Horse /
2026 FDA CVM data 17 reports on file official source
Clydesdale — FDA Adverse Event Profile
Adverse-event records and label data for Clydesdale (Horse), sourced from the FDA Center for Veterinary Medicine. Refreshed as new reports are filed. Cite PlainBreed when reusing this analysis.
Clydesdale (Horse) has 17 FDA adverse event reports on record, with 5 deaths reported (2940.0% death rate) — ranking #379 by report volume. The most frequently reported reaction is Application site swelling (2 cases). The top associated drug is Detomidine Hydrochloride. Average age at report: 7.9 years.
Deaths Reported
5
of 17 reports
Death Rate
2940.0%
death-coded share
Avg Age at Report
7.9 yr
269.0 kg avg weight
Death-Coded Outcome Share
Clydesdale death-coded reports 100.0%
Database median
2940.0% of 17 reports involved a death outcome. Read alongside breed popularity, veterinary access, and owner awareness — these shape how many events ever reach the FDA. The 12% comparison line is the rough cross-breed median in the FDA CVM database; values above suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.
Average weight at time of report: 269.0 kg (593.1 lbs)
Top Reported Reactions
Application site swelling 2
Localised oedema (not application site) 2
Death by euthanasia 2
Fever 2
Uncoded sign 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Underdose 2
Death 2
Application site pain 1
Localised pain NOS (see other 'SOCs' for specific pain) 1
Skin inflammation NOS 1
Sudden death 1
Appetite loss 1
Lateral recumbency 1
Sternoabdominal recumbency 1
Most Referenced Drugs
Detomidine Hydrochloride 2
Acepromazine Maleate 2
Ivermectin(1.55%)/Praziquantel(7.75%) Paste 2
Omeprazole 37% Oral Paste 2
Omeprazole 2
Ivermectin, Praziquantel 1
Moxidectin 1
Doramectin 1
Pyrantel Tartrate 1
Polysulfated Glycosaminoglycan 1
Unspecified Polyglycan 1
Firocoxib 1
Unspecified Hoof Supplement 1
Vitamins 1
Fenbendazol Oral Paste 1
Outcome Breakdown
Outcome Unknown
5 (29.4%)
Recovered/Normal
4 (23.5%)
Euthanized
3 (17.6%)
Ongoing
3 (17.6%)
Died
2 (11.8%)
Gender Distribution
Male 11 (64.7%)
Female 4 (23.5%)
Mixed 1 (5.9%)
Unknown 1 (5.9%)
Reports by Year
| Year | Reports | Trend |
|---|---|---|
| 2010 | 1 | |
| 2012 | 1 | |
| 2013 | 2 | |
| 2014 | 2 | |
| 2015 | 1 | |
| 2016 | 2 | |
| 2019 | 1 | |
| 2020 | 1 | |
| 2021 | 1 | |
| 2022 | 2 | |
| 2023 | 2 | |
| 2024 | 1 | |
Clydesdale Pet Health Insights
Across the FDA Center for Veterinary Medicine adverse event database, Clydesdale accounts for 17 submitted reports and currently ranks #379 by report volume within the horse population. Of those reports, 5 involved a death outcome — a 2940.0% case-fatality figure calculated directly from the underlying FDA records rather than from external mortality studies. The mean age at time of reporting is 7.9 years, with an average recorded body weight of 269.0 kg (593.1 lbs). These figures reflect the voluntary reporting pool only and should be read alongside breed popularity, veterinary access, and owner awareness — all of which shape how many events ever reach the FDA.
The most frequently reported clinical signs for Clydesdale are Application site swelling (2 reports), Localised oedema (not application site) (2 reports), Death by euthanasia (2 reports), together capturing a substantial share of the top-reaction traffic seen in this breed's record. On the product side, Detomidine Hydrochloride appears in 2 reports and is the single most-referenced drug, followed by Acepromazine Maleate (2) and Ivermectin(1.55%)/Praziquantel(7.75%) Paste (2). Counts like these surface which therapeutic classes dominate the reporting stream — useful context when comparing reactions across breeds of the same horse species.
Outcome coding on the 17 reports with a recorded status is dominated by Outcome Unknown (29.4% of coded outcomes). Annual submission volume ranges from 2,010 to 2,024 reports across the 12 years on file, indicating the reporting trend is shaped as much by awareness cycles as by underlying clinical events. Because FDA adverse event reports describe correlation rather than causation, these numbers are most useful as a signal of where to ask further questions with a veterinarian — not as a standalone risk score for any individual horse.
Understanding Clydesdale Adverse Event Data
Clydesdale has 17 adverse event reports on file. Lower report volumes may reflect a less common breed, lower reporting rates, or genuinely fewer adverse events.
The 2940.0% death rate is above average, though this statistic should be interpreted cautiously. Death reports may be overrepresented because serious outcomes are more likely to be reported than mild reactions.
The most frequently referenced drug in adverse reports is Detomidine Hydrochloride, appearing in 2 reports. This may indicate widespread use of the medication rather than a specific safety concern for Clydesdale.
Other Horse Breeds
Frequently Asked Questions
How many FDA adverse event reports involve Clydesdale? ▼
There are 17 adverse event reports involving Clydesdale in the FDA database, with 5 reports involving death (2940.0% death rate). Clydesdale ranks #379 by report volume.
What are the most common adverse reactions reported for Clydesdale? ▼
The most commonly reported adverse reactions for Clydesdale are Application site swelling (2 reports), Localised oedema (not application site) (2 reports), Death by euthanasia (2 reports), Fever (2 reports), Uncoded sign (2 reports).
What drugs are most frequently associated with Clydesdale adverse events? ▼
The drugs most frequently referenced in Clydesdale adverse event reports are Detomidine Hydrochloride (2 reports), Acepromazine Maleate (2 reports), Ivermectin(1.55%)/Praziquantel(7.75%) Paste (2 reports), Omeprazole 37% Oral Paste (2 reports), Omeprazole (2 reports).
What is the average age of Clydesdale in adverse event reports? ▼
The average age of Clydesdale at the time of adverse event reports is 7.9 years, with an average weight of 269.0 kg (593.1 lbs).
Does a high number of adverse event reports mean Clydesdale is unhealthy? ▼
No. FDA adverse event reports are voluntarily submitted and do not prove causation. Popular breeds with more veterinary visits tend to have more reports. The data reflects reporting patterns, not actual incidence rates. Always consult a veterinarian for health decisions.
Where does this Clydesdale safety data come from? ▼
All data comes from the FDA Center for Veterinary Medicine's adverse event reporting system. Pet owners, veterinarians, and manufacturers voluntarily submit reports about adverse events potentially linked to animal drugs and other products.
Guides & Resources
Understanding Adverse Events
What FDA reports are and how they are collected
Breed-Specific Risks
Why some breeds appear in more adverse event reports
Pet Medication Safety
Evaluating medication risks using FDA data
Most Reported Medications
Drugs that appear most in adverse event reports
How FDA CVM Tracks Events
The reporting process and database limitations
Related Data Sources
Data Sources & Methodology
Adverse event data sourced from the FDA Center for Veterinary Medicine via the openFDA Animal & Veterinary Adverse Events API. Reports are voluntarily submitted by pet owners, veterinarians, and product manufacturers.
Clydesdale ranks #379 by total report volume. Death rate (2940.0%) reflects the proportion of reports involving death and should not be interpreted as a breed-specific mortality rate. Reporting biases, breed popularity, and veterinary access all influence report counts.
Read our methodology — how this data is sourced, computed, and verified.
Related
Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial